PlainRecalls
FDA Drug Low Class III Ongoing

Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg, 100-count Bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale -Bardez, Goa 403513, India, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-295-01

Reported: August 30, 2023 Initiated: August 14, 2023 #D-1095-2023

Product Description

Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg, 100-count Bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale -Bardez, Goa 403513, India, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-295-01

Reason for Recall

Subpotent: Out of Specification for Assay Test at the 3-month time point.

Details

Units Affected
1,200 bottles
Distribution
nationwide in the U.S.
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mg, 100-count Bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd. Colvale -Bardez, Goa 403513, India, Manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-295-01. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 1,200 bottles.
Why was this product recalled?
Subpotent: Out of Specification for Assay Test at the 3-month time point.
Which agency issued this recall?
This recall was issued by the FDA Drug on August 30, 2023. Severity: Low. Recall number: D-1095-2023.